JP Morgan Chase
KALA icon

JP Morgan Chase’s KALA BIO KALA Stock Holding History

JP Morgan Chase’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed -$20K – 5537
2020
Q1 		$20K Buy
+1
New +$16K ﹤0.01% 4951

Other funds holding KALA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's KALA Position: Q1 2026 in Review

JP Morgan Chase increased its KALA BIO (KALA) stake by 59,900% in Q1 2026, buying an estimated $12.7K and bringing the position to 600 shares worth $5.13K. The position accounts for ﹤0.01% of the portfolio, ranked #6883.

JP Morgan Chase first reported a position in KALA in Q3 2017 and has held it in 35 quarters since. The position peaked at $4.15M in Q4 2017. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

  • JP Morgan Chase held 600 shares of KALA BIO worth $5.13K as of Q1 2026.
  • JP Morgan Chase bought 599 KALA BIO shares in Q1 2026, an estimated $12.7K.
  • KALA BIO made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6883 holding.
  • JP Morgan Chase first reported a position in KALA BIO in Q3 2017 and has held it in 35 quarters since.
  • JP Morgan Chase's KALA BIO position peaked at $4.15M in Q4 2017.
  • 28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.